Xillix Technologies Corp.

Xillix Technologies Corp.

July 08, 2005 09:04 ET

Xillix Announces Onco-LIFE'TM' Sales Management Team

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - July 8, 2005) - Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy for the early detection of cancer, today announced its Onco-LIFE™ Sales Management team responsible for global sales. Joining Patrick du Monceaux, Vice President Sales & Marketing and David Marsh, Director North American Sales are David Vogt - Western Region US Sales Manager, Victor Marone - Eastern Region US Sales Manager, David Phillips - European Business Manager, Northern Region, and Martine Forissier - European Business Manager, Southern Region. As announced on May 17, 2005, Xillix's North American Sales Management team will be working with ConMed Endoscopic Technologies (www.conmed.com), the sole distributor of Onco-LIFE in the United States (for the lung application) and in Canada (for both lung and GI applications).

"We are pleased to have assembled such a highly seasoned sales management team with medical device experience," said Patrick du Monceaux, Vice President, Sales & Marketing. "All of our sales managers have strong relationships in the medical community and a wealth of industry-specific expertise which is invaluable as we move forward with sales in Europe, Canada and globally, particularly now with the launch of Onco-LIFE in the U.S., the world's largest medical device market."

In North America, David Marsh, Director of North American Sales, who joined Xillix in the first quarter of 2004, has more than 20 years of sales and marketing experience in the medical device industry, including managing the U.S. sales force for Bard Endoscopic Technologies, a division of CR Bard (now ConMed Endoscopic Technologies). David Vogt, Western Region US Sales Manager, has more than 20 years of progressive sales management experience in the medical device and critical care markets, as both a division and regional manager for several large multi-national corporations. Victor Marone, Eastern Region US Sales Manager, brings more than 10 years of sales and marketing experience to Xillix. During his time at Bard Endoscopic Technologies and GE Healthcare, Victor gained valuable experience introducing new technologies to the medical community and managing capital equipment purchases. David Vogt and Victor Marone have responsibility for driving sales opportunities, sales support and training as well assisting ConMed in their respective regions; both report to David Marsh.

In Europe, David Phillips and Martine Forissier have responsibility for driving sales opportunities, sales support and training, as well as managing Xillix's network of European distributors; both report to Patrick du Monceaux. David Phillips, European Business Manager, Northern Region, brings 17 years experience in implementing and managing successful direct sales operations and distributor networks. In his most recent position with Medtronic Europe, David was Senior Business Manager for the Emergency Response Systems business in the Emerging Markets segment, comprised of Eastern Europe, Middle East, Africa and India. Martine Forissier, European Business Manager, Southern Region, comes to Xillix with extensive experience in the medical device and clinical applications business. In her most recent position with Medtronic Europe, Martine was the European Director of Commercial Business for the Emergency Response Systems, comprised of Western Europe and supporting other areas in Europe and the Emerging Markets. Sales opportunities in other global markets including Asia, are currently being managed directly by Mr. du Monceaux.

About Xillix

Xillix Technologies Corp. is a Canadian medical device company and the world leader in fluorescence endoscopy for improved cancer detection. Xillix's latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. An international multicenter lung cancer clinical trial of Onco-LIFE demonstrated a 325% per-lesion improvement in the detection of early lung cancer (moderate-severe dysplasia and carcinoma in situ) and a 250% per-patient improvement compared to white-light alone. Onco-LIFE is approved for sale in the United States for the lung application and in Europe and Canada for both lung and GI applications. Onco-LIFE is compact, user-friendly and is compatible with a wide range of endoscopes and endoscopic accessories to help maximize global market acceptance

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated March 31, 2005.

The Company is listed on the Toronto Stock Exchange under the trading symbol "XLX".

Contact Information